Why Two Peptides Instead of One
The nickname is a marketing flourish, but the reasoning is real. BPC-157 and TB-500 are two of the most studied recovery peptides in preclinical work, and they target different parts of the same problem. BPC-157 is studied in research as a localized tissue-repair compound that supports angiogenesis, fibroblast activity, and the tendon-to-bone interface. TB-500, a synthetic fragment of Thymosin Beta-4, has been studied for cellular migration, actin regulation, and systemic recovery effects. Together they hit both the injury site and the cellular machinery moving in to fix it.
That is the entire logic of the Wolverine stack: one peptide brings the repair crew to the site, the other helps that crew move and replicate. The pairing has become popular in athletic recovery, post-surgical rehab, and chronic soft-tissue settings. The honest version is more careful than what shows up on bodybuilding forums. Human clinical trials remain limited, dosing is studied in research rather than fully clinically standardized, and individual results vary.
BPC-157 in the Stack: What It Does
BPC-157, short for Body Protection Compound 157, is a synthetic peptide derived from a protective protein sequence found in gastric juice. It is most consistently studied in research for three things: angiogenesis (new blood vessel formation into damaged tissue), collagen and fibroblast activity (the structural matrix tendons and ligaments depend on), and reduced local inflammation in soft-tissue injury models. We covered the mechanisms in more depth in our BPC-157 dosage for tendon healing guide. For the stacking conversation, the relevant point is that BPC-157 is local. Injection placement near the injury is reported to achieve a meaningfully higher tissue concentration than a distal abdominal shot.
TB-500 in the Stack: What It Does
TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring protein involved in actin regulation and cell motility. Where BPC-157 is local, TB-500 has been studied for systemic recovery effects: cellular migration (signaling cells to move toward damaged tissue), angiogenesis support through a different pathway than BPC-157, and immune-modulating activity that may help reduce the chronic low-grade inflammation that delays healing. TB-500 is dosed less frequently than BPC-157 because of its half-life and systemic distribution profile. Most published protocols use weekly or twice-weekly dosing rather than daily.
How the Two Peptides Work Together
The reason this combination has stuck around is mechanistic complementarity. Tissue repair is a sequence of overlapping phases: inflammation, proliferation, and remodeling. BPC-157 is studied in research as influencing the proliferation phase locally, where new vessels and collagen need to organize at the injury site. TB-500 has been studied for the migration phase systemically, where cells from elsewhere in the body need to reach the site. Addressing both phases gives the recovery process more support than either peptide alone.
The stack is not a replacement for rehab, loading, or surgical follow-through. Peptides may be considered for eligible patients as an adjunct that supports the body's recovery process. The patients who get the most out of a Wolverine protocol are the ones who pair it with structured physical therapy and progressive loading.
The Dose Ranges Most Often Cited in Research
Across published protocols and provider-supervised programs, stacked dosing tends to land within a fairly narrow band. The numbers below are what appears repeatedly in the literature.
| Use case | BPC-157 daily | TB-500 weekly | Cycle length |
|---|---|---|---|
| Acute soft-tissue injury or recent tear | 400 to 500 mcg total, split twice daily | 4 to 5 mg, split across two injections | 4 to 6 weeks |
| Chronic tendinopathy or stubborn overuse injury | 250 to 300 mcg once daily | 2 to 3 mg, weekly single dose | 6 to 8 weeks |
| Post-surgical recovery (cleared by surgeon) | 500 to 750 mcg total, split twice daily | 4 to 5 mg, split across two injections | 8 to 12 weeks |
| Maintenance after recovery | 200 to 250 mcg once daily, 5 days a week | 2 mg weekly | 4 to 6 weeks, 2 to 3 times a year |
Two patterns matter. The acute phase runs higher and more frequent because the inflammatory and proliferation windows are when both peptides have the most leverage. Chronic and maintenance phases run lower and longer because the goal shifts to extracellular matrix remodeling. A provider in our network reviews which pattern applies before a protocol is finalized. This information is studied in research and shared for education. Individual results vary.
Cycle Length, Breaks, and What Not to Do
Open-ended dosing without a defined cycle is not how the published work was conducted. Reasonable cycle hygiene for a Wolverine stack:
- Define the cycle length based on the injury phase (acute, chronic, post-surgical, maintenance)
- Take a structured break of at least 4 to 8 weeks between cycles unless a provider directs otherwise
- Reassess at the end of each cycle: pain, function, return-to-activity tolerance
- Pair every cycle with appropriate rehab. The peptides support a process; they do not replace loading and mobility work
- Do not add new compounds mid-cycle without provider review
What not to do shows up too often in forum posts: ordering "research only" peptides from an unlicensed seller, dosing by gut feel, and skipping every follow-up. We cover the broader supply landscape in our prescribed peptides vs research peptides guide.
Reported Timelines and Realistic Expectations
Across patient reports and clinical wellness center summaries, reported timelines for the Wolverine stack tend to follow a similar shape:
- Weeks 1 to 2: Reduced inflammation and pain. Mobility starts to improve in stubborn areas
- Weeks 3 to 4: Better tolerance for load-bearing activity. Tendon and joint resilience start to feel more reliable
- Weeks 4 to 8: Patients report improved function during sport-specific or rehab loading, fewer flare-ups, and steadier baseline comfort
- After cycle: A structured break is when remodeling consolidates. The common mistake is restarting too aggressively
Individual results vary. Severity of injury, age, training context, sleep, nutrition, and rehab quality all matter. Outcomes are individual.
Who the Wolverine Stack Fits, and Who It Does Not
The stack may be considered for eligible patients in a fairly specific set of situations. Reasonable candidates often look like this:
- Chronic tendinopathy (Achilles, patellar tendon, rotator cuff, elbow) that has not responded to traditional rehab
- Post-surgical patients cleared by their surgeon for adjunct support after orthopedic procedures
- Active patients prone to overuse injuries who keep cycling through the same flare-ups
- Athletes returning from a soft-tissue tear who want structured biological support layered onto rehab
The stack is generally not appropriate for patients with active malignancy, those who are pregnant or breastfeeding, anyone with significant uncontrolled inflammatory or autoimmune conditions, or patients without a clear injury or recovery goal. A licensed-provider evaluation is where these factors get reviewed, not a checkout flow. If you want to read more broadly about how peptide therapy fits into a wellness plan, our peptide therapy 101 guide covers the foundations.
Compounded Prescription vs Grey-Market Research Peptides
The BPC-157 and TB-500 market is split into two very different supply chains, and the cost difference between them is much smaller than the safety difference. Compounded peptides from a US-licensed compounding pharmacy are a different product than a "research use only" vial from an unlicensed reseller.
What you should expect from a legitimate program: a licensed-provider evaluation including medical history and injury context before any prescription is issued, a named US-licensed compounding pharmacy with a verifiable license, clear product labeling intended for human use under provider supervision, sterility and potency testing on each lot, a defined protocol with cycle length and follow-up, and real clinical support if something feels off mid-cycle.
Red flags for a grey-market source: labeling that says "research use only" or "not for human consumption," no prescription and no licensed-provider evaluation, overseas shipping with no US pharmacy license, stockpile discounts, and no batch testing data on request. The savings on a grey-market source are not worth the unknowns about what is actually in the vial.
How Madison Meds Approaches the Wolverine Stack
Madison Meds is a family-owned telehealth platform that connects eligible patients with an independent network of US-licensed providers. We are not a clinic and we do not represent providers as our staff. Through Madison Meds, the compounded Wolverine stack (BPC-157 plus TB-500) is available and may be considered for eligible patients after a licensed-provider evaluation, with the medication dispensed by a US-licensed compounding pharmacy. The intake covers injury history, prior imaging or surgical reports, current rehab status, medications, training context, and goals. A provider then determines whether the stack is appropriate, what protocol applies, and how follow-up will work.
If you are an athlete with stubborn tendinopathy, a post-surgical patient cleared by your surgeon, or someone weighing whether a structured peptide stack fits your recovery, the right starting point is a licensed-provider evaluation rather than a forum-sourced vial.
Frequently Asked Questions
What is the Wolverine stack and what is it studied in research for?
The Wolverine stack is the combination of BPC-157 and TB-500, two peptides studied in research for tissue repair, angiogenesis, and recovery from soft-tissue injuries. Educational content. Not medical advice. Outcomes are individual.
What dose of BPC-157 and TB-500 is studied in research for a stacked protocol?
Stacked protocols are typically studied at 250 to 500 mcg of BPC-157 per day with 2 to 5 mg of TB-500 per week, split across two or three weekly injections, over a 6 to 8 week cycle. A licensed-provider evaluation should set the dose for your situation.
How long does the Wolverine stack take to work?
Reported timelines vary. Many users describe reduced inflammation and pain within 1 to 2 weeks, improved mobility around weeks 3 to 4, and meaningful tissue recovery between weeks 4 and 8. Individual results vary and rehab matters.
Is the Wolverine stack FDA approved?
No. Neither BPC-157 nor TB-500 is an FDA-approved drug. Compounded BPC-157 and TB-500 dispensed by a US-licensed compounding pharmacy after a licensed-provider evaluation is a different supply category than research-only peptides sold without a prescription.
Who is the Wolverine stack for?
It may be considered for eligible patients with stubborn tendinopathy, post-surgical recovery cleared by a surgeon, chronic soft-tissue injuries, or active patients prone to overuse injuries. A licensed-provider evaluation determines fit. Individual results vary.
Educational content. Not medical advice. Compounded medications are not FDA-approved drugs. A licensed provider in the Madison Meds network reviews your medical history before any prescription, and not all patients are appropriate candidates for peptide therapy. Individual results vary. Consult licensed providers about treatment decisions.
See if the Wolverine stack is right for your recovery
A licensed provider in the Madison Meds network will review your injury, training context, and goals and determine whether a BPC-157 plus TB-500 stack is appropriate. The compounded Wolverine stack may be considered for eligible patients after a licensed-provider evaluation, with the medication dispensed by a US-licensed compounding pharmacy.
View the Wolverine Stack